Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges

作     者：Federico Pinro Jaime Poniachik Ezequiel Ridruejo Marcelo Silva 

作者机构：Hospital Universitario AustralFacultad de Ciencias BiomédicasUniversidad AustralPilarBuenos Aires B1629HJArgentina American Liver Research Educational and Awareness NetworkBuenos Aires B1629HJArgentina HepatologyHospital Clínico Universidad de ChileSantiago de ChileRegión Metropolitana Santiago 46010Chile Santa MaríaSantiago de ChileRegión Metropolitana Santiago 834-0518Chile Médica e Investigaciones Clínicas Norberto QuirnoCiudad de Buenos Aires C1425ASGArgentina 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2018年第24卷第37期

页      面：4224-4229页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Latin America Liver cancer Limitations Challenge 

摘      要：Latin America, a region with a population greater than 600000000 individuals, is well known due to its wide geographic, socio-cultural and economic heterogeneity. Access to health care remains as the main barrier that challenges routine screening, early diagnosis and proper treatment of hepatocellular carcinoma(HCC). Therefore, identification of population at risk, implementation of surveillance programs and access to curative treatments has been poorly obtained in the region. Different retrospective cohort studies from the region have shown flaws in the implementation process of routine surveillance and early HCC diagnosis. Furthermore, adherence to clinical practice guidelines recommendations assessed in two studies from Brazil and Argentina demonstrated that there is also room for improvement in this field, similarly than the one observed in Europe and the United States. In summary, Latin America shares difficulties in HCC decision-making processes similar to those from developed countries. However, a transversal limitation in the region is the poor access to health care with the consequent limitation to standard treatments for overall population. Specifically, universal health care access to the different World Health Organization levels is crucial, including improvement in research, education and continuous medical training in order to expand knowledge and generation of data promoting a continuous improvement in the care of HCC patients.